Scientists from National Taiwan University (NTU) and Linkou Chang Gung Memorial Hospital (CGMH) have developed a precision-engineered nanoplatform to conquer glioblastoma (GBM), the most aggressive and deadly form of brain cancer. Treating glioblastoma is notoriously difficult due to its diffuse infiltration, the formidable blood-brain barrier (BBB), and a highly complex tumor microenvironment. A major component of this protective microenvironment are cancer-associated fibroblasts (CAFs)—stromal "helper" cells that support tumor growth and suppress the immune system.
Crucially, a specific marker called fibroblast activation protein (FAP) is widely expressed not only by these supportive CAFs but also by the glioblastoma cells themselves, presenting a highly promising and comprehensive target for drug delivery.
In a new study published in the journal Theranostics, the research team reveals a breakthrough approach to overcome these hurdles using a modular ferritin-based drug carrier (FDC).
To turn natural ferritin into a highly specific tumor-hunting vehicle, the team utilized site-specific Sortase A-mediated ligation. This advanced enzymatic technique acts like a highly precise "molecular stapler," allowing researchers to seamlessly attach an optimized FAP-targeting ligand to the surface of the ferritin shell, all while preserving the protein's natural structure and drug-loading capacity.
Inside this engineered nanocage, the team stably encapsulated monomethyl auristatin E (MMAE), an exceptionally potent cytotoxin. The result is a powerful dual-targeting nanocarrier that strikes at the heart of the disease: it utilizes ferritin's natural ability to bind to transferrin receptor 1 (TfR1) while simultaneously homing in on FAP to eliminate both the primary tumor cells and their protective stromal allies.
When tested in orthotopic glioblastoma mouse models, this targeted approach demonstrated remarkable precision. The carrier utilizes a pH-responsive mechanism, remaining stable in the bloodstream but rapidly releasing the highly toxic MMAE payload once inside the acidic microenvironment of the tumor.
Compared to administering free MMAE, this targeted approach significantly enhanced cellular uptake, reduced tumor burden, and prolonged survival, while safely ignoring healthy brain tissue and effectively minimizing systemic toxicity.
Yi-Hsiang Tseng, the first author of the study and a researcher at NTU, explained, "Our approach acts like a guided missile combined with a Trojan Horse. By using a natural protein that already knows how to enter the brain, and adding our special tumor-finding radar, we can drop an exceptionally strong drug exactly where the cancer hides, leaving healthy areas completely safe."
The benefits extended far beyond localized cell death. Using cutting-edge spatial transcriptomic analyses and immunohistochemistry, the researchers discovered that this targeted therapy fundamentally reshapes the tumor microenvironment.
By attacking the CAFs and the tumor simultaneously, the treatment breaks down the tumor's defensive stroma and bridges the physical gap between the tumor and the body's natural defense system. This stromal modulation successfully recruits cytotoxic immune cells deep into the tumor bed and activates multiple immune pathways, turning an immunosuppressive environment into a highly reactive one.
Moving forward, the research team aims to leverage these novel insights into the stromal-immune dynamics of glioblastoma. By continuously optimizing this modular platform, their ultimate goal is to combine this CAF-modulating technology with existing immunotherapies to offer a real-world, durable treatment for cancer patients.
"This platform opens an entirely new frontier in treating brain cancer," said Dr. Feng-Ting Huang, co-corresponding author of the study and an Associate Professor in the Department of Biochemical Science and Technology at National Taiwan University.
"For decades, glioblastoma has been notoriously difficult to treat because it acts as an 'immune-cold' tumor. By successfully engineering a dual-targeting carrier that breaches the blood-brain barrier and recruits cytotoxic immune cells, we are effectively turning these cold tumors 'hot.' This breakthrough is a crucial step toward offering real, transformative hope to patients facing this devastating diagnosis."
To see article on Phys.org: https://phys.org/news/2026-03-scientists-trojan-horse-conquer-aggressive.html